Compounded Bioidentical Hormone Therapy: Identifying Use Trends and Knowledge Gaps Among US Women

Overview

Journal Menopause

Specialty Gynecology & Obstetrics

Date 2015 Feb 19

PMID 25692877

Citations 16

Authors

JoAnn V Pinkerton

Nanette Santoro

Affiliations

Soon will be listed here.

Abstract

Objective: Two surveys (Harris and Rose surveys) were conducted to quantify the use of compounded hormone therapy (CHT; or bioidentical hormone therapy) among perimenopausal and postmenopausal women in the United States, to assess women's knowledge of CHT versus Food and Drug Administration (FDA)-approved hormone therapy, and to gather information on menopausal experience.

Methods: The Harris survey was administered to 801 women aged 45 to 60 years who had experienced at least one menopausal symptom. The Rose survey was administered to 2,044 women aged 40 years or older who were ever users of hormone therapy. Women were queried about menopausal symptoms, hormone therapy use, and knowledge of CHT. Findings from the Rose survey were extrapolated using US Census Bureau data and prescription claims for FDA-approved hormone therapy to estimate the prevalence of CHT use.

Results: According to extrapolations using Rose data, up to 2.5 million US women aged 40 years or older may use CHT annually, accounting for 28% to 68% of hormone therapy prescriptions. Harris data showed that 86% of women surveyed were unaware that CHT products are not FDA-approved. The Rose survey asked a subset of 1,771 women whether their hormone therapy had been personalized based on hormone levels; 21% (378) answered "yes" whereas 27% (476) did not know. In both surveys, most hormone therapy users stated that their physician had recommended the treatment.

Conclusions: We estimate that 1 million to 2.5 million US women aged 40 years or older use CHT. The data suggest that many women are unaware that compounded hormones have not been evaluated or approved by the FDA. Providers have an educational opportunity to ensure that women considering hormone therapy understand the risks and benefits of inadequately regulated CHT.

Citing Articles

Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies.

Stanczyk F, Niu C, Azen C, Mirkin S, Amadio J Menopause. 2019; 26(9):966-971.

PMID: 31453957 PMC: 6738624. DOI: 10.1097/GME.0000000000001356.

Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.

Kaunitz A, Pinkerton J, Manson J Menopause. 2019; 26(4):338-340.

PMID: 30789455 PMC: 6435398. DOI: 10.1097/GME.0000000000001313.

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

Constantine G, Revicki D, Kagan R, Simon J, Graham S, Bernick B Menopause. 2018; 26(5):513-519.

PMID: 30516713 PMC: 6493698. DOI: 10.1097/GME.0000000000001261.

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.

Simon J, Kaunitz A, Kroll R, Graham S, Bernick B, Mirkin S Menopause. 2018; 26(5):506-512.

PMID: 30489424 PMC: 6493699. DOI: 10.1097/GME.0000000000001271.

Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.

Constantine G, Kessler G, Graham S, Goldstein S J Womens Health (Larchmt). 2018; 28(2):237-243.

PMID: 30484734 PMC: 6390656. DOI: 10.1089/jwh.2018.6956.

References

Buist D, Newton K, Miglioretti D, Beverly K, Connelly M, Andrade S . Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004; 104(5 Pt 1):1042-50. DOI: 10.1097/01.AOG.0000143826.38439.af. View

Guthrie J, Dennerstein L, Taffe J, Lehert P, Burger H . Hot flushes during the menopause transition: a longitudinal study in Australian-born women. Menopause. 2005; 12(4):460-7. DOI: 10.1097/01.GME.0000155200.80687.BE. View

Gold E, Colvin A, Avis N, Bromberger J, Greendale G, Powell L . Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006; 96(7):1226-35. PMC: 1483882. DOI: 10.2105/AJPH.2005.066936. View

Cirigliano M . Bioidentical hormone therapy: a review of the evidence. J Womens Health (Larchmt). 2007; 16(5):600-31. DOI: 10.1089/jwh.2006.0311. View

Sandini L, Pentti K, Tuppurainen M, Kroger H, Honkanen R . Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study . Menopause. 2007; 15(2):282-9. DOI: 10.1097/gme.0b013e3181334b6c. View

Boothby L, Doering P . Bioidentical hormone therapy: a panacea that lacks supportive evidence. Curr Opin Obstet Gynecol. 2008; 20(4):400-7. DOI: 10.1097/GCO.0b013e3283081ae9. View

MacLennan A, Gill T, Broadbent J, Taylor A . Continuing decline in hormone therapy use: population trends over 17 years. Climacteric. 2009; 12(2):122-30. DOI: 10.1080/13697130802666251. View

Jungheim E, Colditz G . Short-term use of unopposed estrogen: a balance of inferred risks and benefits. JAMA. 2011; 305(13):1354-5. DOI: 10.1001/jama.2011.405. View

Iftikhar S, Shuster L, Johnson R, Jenkins S, Wahner-Roedler D . Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. J Womens Health (Larchmt). 2011; 20(4):559-65. DOI: 10.1089/jwh.2009.1915. View

10.

Sayakhot P, Vincent A, Teede H . Breast cancer and menopause: perceptions of diagnosis, menopausal therapies and health behaviors. Climacteric. 2011; 15(1):59-67. DOI: 10.3109/13697137.2011.603772. View

11.

. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012; 19(3):257-71. PMC: 3443956. DOI: 10.1097/gme.0b013e31824b970a. View

12.

Steinkellner A, Denison S, Eldridge S, Lenzi L, Chen W, Bowlin S . A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause. 2012; 19(6):616-21. DOI: 10.1097/gme.0b013e31824bb039. View

13.

. Committee opinion No. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012; 120(2 Pt 1):411-5. DOI: 10.1097/AOG.0b013e318268049e. View

14.

Sprague B, Trentham-Dietz A, Cronin K . A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012; 120(3):595-603. PMC: 3607288. DOI: 10.1097/AOG.0b013e318265df42. View

15.

Sellers S, Utian W . Pharmacy compounding primer for physicians: prescriber beware. Drugs. 2012; 72(16):2043-50. PMC: 3695671. DOI: 10.2165/11640850-000000000-00000. View

16.

Spark M, Willis J, Byrne G . Compounded progesterone: why is it acceptable to Australian women?. Maturitas. 2012; 73(4):318-24. DOI: 10.1016/j.maturitas.2012.09.003. View

17.

Siyam T, Yuksel N . Beliefs about bioidentical hormone therapy: a cross-sectional survey of pharmacists. Maturitas. 2012; 74(2):196-202. DOI: 10.1016/j.maturitas.2012.11.007. View

18.

Moyer V . Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 158(1):47-54. DOI: 10.7326/0003-4819-158-1-201301010-00553. View

19.

de Villiers T, Pines A, Panay N, Gambacciani M, Archer D, Baber R . Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3):316-37. DOI: 10.3109/13697137.2013.795683. View

20.

Panay N, Hamoda H, Arya R, Savvas M . The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause Int. 2013; 19(2):59-68. DOI: 10.1177/1754045313489645. View